Tech Company Financing Transactions

Sagent Pharmaceuticals Funding Round

Private investors participated in a $40 million Series B funding round for Sagent Pharmaceuticals. The round was announced on 4/9/2010.

Transaction Overview

Announced On
4/9/2010
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1901 N. Roselle Rd. 450
Schaumburg, IL 60195
USA
Email Address
Overview
SAGENT is a forward-thinking specialty injectables company that goes beyond just listening to what our customers have to say. We're committed to responding to what we hear. With speed, with flexibility, and with efficiency.
Profile
Sagent Pharmaceuticals LinkedIn Company Profile
Social Media
Sagent Pharmaceuticals Company Twitter Account
Company News
Sagent Pharmaceuticals News
Facebook
Sagent Pharmaceuticals on Facebook
YouTube
Sagent Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jeffrey Yordon
  Jeffrey Yordon LinkedIn Profile  Jeffrey Yordon Twitter Account  Jeffrey Yordon News  Jeffrey Yordon on Facebook


 

 

Browse more venture capital transactions:

Prev: 4/8/2010: Karmasphere venture capital transaction
Next: 4/9/2010: MedMinder Systems venture capital transaction

 

Share this article

 


Where The Data Comes From

We report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary